Anti-vascular agent Combretastatin A-4-P modulates Hypoxia Inducible Factor-1 and gene expression

Article English OPEN
Dachs, G.U.; Steele, A.J.; Coralli, C.; Kanthou, C.; Brooks, A.C.; Gunningham, S.P.; Currie, M.J.; Watson, A.I.; Robinson, B.A.; Tozer, G.M.;
  • Publisher: BioMed Central
  • Journal: BMC Cancer,volume 6,issue 1,pages280-280 (issn: 1471-2407, eissn: 1471-2407)
  • Publisher copyright policies & self-archiving
  • Related identifiers: doi: 10.1186/1471-2407-6-280, pmc: PMC1702548
  • Subject: Genetics | Research Article | RC254-282 | VASCULAR-TARGETING AGENT, ENDOTHELIAL-CELLS, A4 PHOSPHATE, A-4 PHOSPHATE, KAPPA-B, SIGNAL-TRANSDUCTION, ANGIOGENESIS, CANCER, TRIAL, FACTOR-1-ALPHA | Cancer Research | Oncology | Neoplasms. Tumors. Oncology. Including cancer and carcinogens

<p>Abstract</p> <p>Background</p> <p>A functional vascular network is essential for the survival, growth and spread of solid tumours, making blood vessels a key target for therapeutic strategies. Combretastatin A-4 phosphate (CA-4-P) is a tubulin-depolymerising agent in... View more
Share - Bookmark